Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 1997

View Archived Issues

Oral and nasal sumatriptan studied for migraine

Clinical results presented for Knoll's PEG-hirudin

Clinical pharmacokinetics and safety reported for Sankyo's MAO-A inhibitor

Clinical pharmacokinetics and bradycardic activity of S-16257

Pentoxifylline demonstrates gastroprotective effects in patient study

First combination anti-HIV drug approved in U.S.

Symphony discloses AMPA antagonists

Inhibitors of sCD23 production developed at SmithKline Beecham

Zeneca presents new antibacterials active against resistant pathogens

Na+/K+-exchange inhibitors from Fujisawa

Rhone-Poulenc Rorer discloses new AMPA/NMDA receptor antagonists

Antiviral thienoxazinones prepared at SKB

LY-333334: new bone anabolic agent from Lilly

PathoGenesis presents new antimycobacterial agents

Alza to market IVAX urology products in U.S., Canada

Intron A/ribavirin combination for HCV: preliminary phase III results

Seroquel cleared for marketing in U.S.

Amgen to emphasize calcimimetics program; preliminary phase II results reported for R-568

LF-08-0299 both prevents and reverses kidney rejection in dogs

Patient recruitment for verteporfin phase III trials exceeds goals

New class of antifungal agents developed at Glaxo Wellcome

SNX-111 study in head trauma resumed

Bayer evaluates novel heteroaryl oxazolidinones

Pfizer seeks U.S. and European approval for Viagra

Techniclone submits IND for malignant glioma

Clinical results on neuraminidase inhibitor presented at ICAAC

Inex seeks Canadian approval to commence Onco TCS trials for lymphoma

Warner-Lambert reports dihydropyrone HIV protease inhibitors

Canadian regulatory review of modafinil continues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...